This archive preserves the scientific news of the previous oncodianova.com website. The three entries below announced congress posters presented at the AACR Annual Meeting 2018. The announcement texts are reproduced verbatim, including original spelling; only layout and download addresses were adapted. Congress posters are conference presentations — they are not peer-reviewed publications. ONCOdianova antibodies are for research use only and not intended for use in diagnostic procedures.
Website announcement · 15 May 2018
Prevalence of TIGIT expression in normal tissues, inflammation, and cancer
American Association of Cancer Research (AACR) Annual Meeting, Chicago, Apr 14-18, 2018 – Poster presentation:
Mouse monoclonal antibody TG1 was used for immunohistochemical analysis of routine formalin fixed paraffin embedded tissue sections from normal lymphatic tissues as well as selected inflamations and cancers and compared to expression patterns of PD1.
Data provided by: Institue of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany. Dianova GmbH, Warburgstr. 54, 20354 Hamburg, Germany. Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany.
PDF · 2.5 MB · AACR Annual Meeting 2018 · congress poster, not a peer-reviewed publication
Website announcement · 16 May 2018
High variability of TIGIT expression in Hodgkin’s lymphoma
American Association of Cancer Research (AACR) Annual Meeting, Chicago, Apr 14-18, 2018 – Poster presentation:
To study patterns of TIGIT expression in the T-cell background surrounding malignant cells, including Hodgkin cells, Reed-Sternberg cells and histiocytic cells, a microenvironment tissue microarray (TMA) was constructed. Immunofluorescence studies with monoclonal antibody TG1 have been perfomed to analyse T-cell type specific expression of TIGIT.
Data provided by: Institue of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany. Dianova GmbH, Warburgstr. 54, 20354 Hamburg, Germany. Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany.
PDF · 1.5 MB · AACR Annual Meeting 2018 · congress poster, not a peer-reviewed publication
Website announcement · 12 September 2020
Expression and Significance of PVR-TIGIT/CD226 in Small Cell Lung Cancer
American Association of Cancer Research (AACR) Annual Meeting, Chicago, Apr 14-18, 2018 – Poster presentation:
The “classical” co-inhibitory PD-1/PD-L1 pathway is not very common in SCLC, but IHC-analysis of the expression and significance of PVR (CD155)-TIGIT/CD226 axis in SCLC highlights a potential role for checkpoint blockade of the TIGIT pathway and may represent a potent therapeutic strategy in SCLC therapy.
Data provided by: Hirsch Biomarker Analysis Laboratory, Divison of Medical Oncology, Anschutz Medical Campus, University of Colorado Denver, Aurora, CO, USA. Radiation Oncology Center NU-Med, Elblag, Poland. Department of Tumor Biology, National Kuranyi Institute of Pulmonology, Budapest, Hungary.
PDF · 1.2 MB · AACR Annual Meeting 2018 · congress poster, not a peer-reviewed publication
Congress posters are presentations by the research groups named on each poster. They are not peer-reviewed publications and are not part of the clone-specific publication lists on our product pages. The announcement texts are quoted unchanged from the previous website (2018/2020); statements on therapeutic strategies reflect the poster authors’ research perspective on the TIGIT pathway — they are not statements about ONCOdianova products. ONCOdianova antibodies are for research use only. Not for use in diagnostic procedures.
